Form 4 Filing for Aquestive Therapeutics, Inc.

This filing reports a grant of 82,500 Performance Stock Units (PSUs) to TOTH A ERNEST JR, SVP, Chief Financial Officer of Aquestive Therapeutics, Inc. The PSUs were granted on March 7, 2025, with a transaction price of $0.0. These PSUs are contingent rights to receive one share of the Company's common stock. The performance period for these PSUs is from March 7, 2025, through March 7, 2028. Vesting occurs 100% on March 7, 2028, if performance conditions are met. The performance price is determined by the 30-day average Nasdaq closing price over specified periods. The filing acknowledges that this Form 4 was submitted late due to an inadvertent administrative oversight. The post-transaction number of shares owned is 82,500.